Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT03691714 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Head and Neck Cancer
Head and Neck Cancer
Head and Neck Neoplasms
Metastatic Cancer

Interventions

DRUG: Durvalumab
DRUG: Cetuximab

Sponsor

Trisha Wise-Draper

Collaborators

[object Object]